Literature DB >> 12522890

[Use of acid-suppressive medications in hospitalized patients].

A Noguerado Asensio1, R Rodríguez Barrientos, P Zelaya Castro, A Sánchez Sempere, F Antuña Blanco, E Lutz García, R Quintana de la Cruz, F Estellés Piera, M S Alcázar.   

Abstract

INTRODUCTION: The acid-suppressive medications are used frequently in hospitalized patients, but some studies suggests that their are overused, especially in the treatment of stress ulcer prophylaxis in low-risk patients. This research determine the frequency of use and indications of acid-suppressive medications in hospitalized patients in a internal medical service.
MATERIALS AND METHODS: A at random and retrospective revision of 209 medical records of 661 hospitalized patients during the year 2000 in the V Internal Medical Service of the General University Hospital of Gregorio Marañón (Cantoblanco). DEFINITIONS: Use: any prescription of an acid-suppressive medication, regardless of dosage regimen, in which the patient received at least one dose. Appropriated indication: endoscopical criteria: treatment of active ulcer disease, esophagitis or gastritis. Medical criteria: symptomatic gastroesophageal reflux, dyspepsia, prolonging of previous treatment, as a part of a treatment regimen for H. pylori, relief of dyspepsia caused by nonsteroidal anti-inflammatory drugs, stress ulcer prophylaxis in high risk patients. Inappropriate indication: any other uses were considered not indicated.
RESULTS: Of the 209 patients, a total of 157 (75.1%) received acid-suppressive therapy, average age 76 years old, 89 women (56.7%) and 68 men (43.3%). The admitting diagnoses for the admission were: CHF 34 (21.7%), Pneumonia (16.6%), UTI (15.3%) y COPD 18 (11.5%). The use in hospital ward was 84.7% (133), with inappropriate use 72.2% (96), the cause of prescription "no reason" 52.1% (50), and received proton pump inhibitors 46.9% (45).
CONCLUSIONS: This study show a high frequency of incorrect use of acid-suppressive medications in hospitalized patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12522890

Source DB:  PubMed          Journal:  An Med Interna        ISSN: 0212-7199


  5 in total

Review 1.  A benefit-risk assessment of the use of proton pump inhibitors in the elderly.

Authors:  Gwen M C Masclee; Miriam C J M Sturkenboom; Ernst J Kuipers
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

2.  Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.

Authors:  Issam S Hamadeh; Kenneth P Klinker; Samuel J Borgert; Ashley I Richards; Wenhui Li; Naveen Mangal; John W Hiemenz; Stephan Schmidt; Taimour Y Langaee; Charles A Peloquin; Julie A Johnson; Larisa H Cavallari
Journal:  Pharmacogenet Genomics       Date:  2017-05       Impact factor: 2.089

3.  Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals.

Authors:  Marcello Maggio; Andrea Corsonello; Gian Paolo Ceda; Chiara Cattabiani; Fulvio Lauretani; Valeria Buttò; Luigi Ferrucci; Stefania Bandinelli; Angela Marie Abbatecola; Liana Spazzafumo; Fabrizia Lattanzio
Journal:  JAMA Intern Med       Date:  2013-04-08       Impact factor: 21.873

4.  Acid suppressive agents and risk of Mycobacterium tuberculosis: case-control study.

Authors:  Wen-Hung Hsu; Chao-Hung Kuo; Sophie S W Wang; Chien-Yu Lu; Chung-Jung Liu; Seng-Kee Chuah; Fu-Chen Kuo; Yen-Hsu Chen; Yaw-Bin Huang; Ming-Feng Hou; Deng-Chyang Wu; Huang-Ming Hu
Journal:  BMC Gastroenterol       Date:  2014-05-13       Impact factor: 3.067

5.  Correlation of Proton Pump Inhibitors with Pulmonary Tuberculosis: A Case-Control Study in Taiwan.

Authors:  Kao-Chi Cheng; Kuan-Fu Liao; Cheng-Li Lin; Shih-Wei Lai
Journal:  Front Pharmacol       Date:  2017-07-19       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.